title: Decreased total CD19⁺ B lymphocytes and the occurrence of monoclonal proteins are frequent in ultra-long (30 to 44-year) renal transplant recipients: implications for allograft and patient survival.
abstract: BACKGROUND
  The B-cell signature of tolerance in kidney transplant patients receiving no immunosuppression includes a significant increase in total CD19(+) B cells.
  
  
  METHODS
  We evaluated kidney transplant recipients with primary functioning allografts for 30-44 years receiving minimal immunosuppression to determine whether they have the same CD19(+) B-cell changes or unusual serologic findings. We included 44 kidney allograft recipients with a graft functioning for 30-44 years, who were treated primarily with minimal prednisone and azathioprine. Twenty-four other recipients whose allografts functioned >30 years were unable to be studied (unable to travel, lost to follow-up, deceased).
  
  
  RESULTS
  The number and percentage of CD19(+) B cells were depressed in 70.5% (31/44) and 81.8% (36/44), respectively, of these 44 ultra-long renal transplant recipients. The other major finding was identification by immunofixation of a monoclonal protein (MP) in 45.5% (20/44) of these same recipients. Among the 26 patients with good or excellent renal function (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m(2); group 1), 12 had a single MP for >1 year, 13 no MP, and 1 a double MP. Conversely, in the 18 patients with fair/failed function (eGFR <40 mL/min/1.73 m(2) in 8, or end-stage renal disease after 30 years in 10; group 2), 3 had a transient single MP or free light chains only, 11 no MP, and 4 a double MP (P = .0425).
  
  
  CONCLUSIONS
  These data reveal that about three quarters of ultra-long renal transplant recipients had low CD19(+) B cells, compared with the elevated B-cell signature reported in tolerant kidney recipients, and nearly half (45.5%) had a serum MP that was not associated with low B cells or mortality. Those with a stable single MP had better graft function.
authors.affiliation: Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. braunw@ccf.org
authors.forename: W E
authors.initials: WE
authors.lastname: Braun
authors.forename: D A
authors.initials: DA
authors.lastname: Protiva
authors.forename: J D
authors.initials: JD
authors.lastname: Schold
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood*; D018941:Antigens, CD19 / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D018941:Antigens, CD19